LoginRegister

    Lupin gets USFDA nod to market its skin conditions cream

    Written by Ruby Khatun Khatun   |  
    Lupin gets USFDA nod to market its skin conditions cream

    New Delhi: Drug firm Lupin said it has received the final nod from the US health regulator to market its Clobetasol Propionate cream used for the treatment of various skin conditions.


    The company has received final approval to market its generic Clobetasol Propionate cream USP, 0.05 percent, from the United States Food and Drug Administration (USFDA), Lupin said in a statement.


    The company's product is a generic version of Fougera Pharmaceuticals Inc's Temovate cream, it added.




    The cream "is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses," it added.

    approvalClobetasol Propionate creamFougera Pharmaceuticals Incgenericgeneric versionLupinmarketskin conditionsskin creamTemovate creamUnited States Food and Drug AdministrationUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X